Haemaccel

Haemaccel is a prescription‑only solution for injection that contains the colloid polygeline as its active ingredient. The product is supplied in an unspecified strength and is formulated as an intravenous fluid used to expand plasma volume. As a colloid plasma volume expander, Haemaccel works by increasing oncotic pressure within the bloodstream, helping to restore circulating volume in patients with fluid loss and supporting hemodynamic stability.

Haemaccel is indicated for clinical situations where rapid plasma volume expansion is required.

- Treatment of hypovolemia due to acute blood loss or dehydration. - Management of circulatory shock when immediate volume support is needed. - Intra‑operative fluid replacement to maintain adequate intravascular volume. - Adjunct therapy during major surgery to prevent hypotension. - Support for patients undergoing dialysis who require plasma expansion. - Use in trauma care to stabilize patients before definitive hemorrhage control.

The safety profile of Haemaccel includes a range of observed adverse reactions, which are generally categorized by frequency and severity.

Common: - Mild, transient fever or chills occurring shortly after infusion. - Temporary elevation of blood pressure that resolves without intervention. - Local irritation or pain at the intravenous infusion site. - Nausea or mild gastrointestinal discomfort during or after administration. - Headache or dizziness that subsides within a few hours.

Serious: - Anaphylactic or severe allergic reactions, including rash, bronchospasm, or hypotension. - Pulmonary edema resulting from fluid overload, especially in patients with cardiac dysfunction. - Renal impairment or decreased kidney function in susceptible individuals.

When using Haemaccel, clinicians should consider several precautionary measures to minimize risks and ensure appropriate patient selection.

- Assess cardiac and renal function before administration, as fluid overload may exacerbate heart failure or kidney disease. - Avoid rapid infusion rates; follow recommended administration guidelines to reduce the chance of pulmonary edema. - Use caution in patients with known hypersensitivity to polygeline or other gelatin-derived products. - Monitor vital signs and fluid balance closely during and after infusion. - Do not administer concomitantly with large volumes of crystalloid solutions without adjusting total fluid input.

Haemaccel may interact with other medications or clinical conditions; awareness of these interactions helps guide safe use.

Avoid: - Avoid concurrent use with other colloid volume expanders, as combined oncotic load can increase risk of fluid overload. - Do not give with medications known to cause severe allergic reactions in gelatin-sensitive patients.

Use with caution: - Use cautiously with diuretics, which may alter fluid balance and require adjustment of infusion volume. - Co‑administration with anticoagulants may enhance bleeding risk due to dilutional effects; monitor coagulation parameters. - Caution is advised when combined with drugs that affect renal function, such as aminoglycosides or NSAIDs, to prevent further kidney impairment.